Bio-Rad Lab-B | 10-Q: FY2025 Q2 Revenue: USD 651.6 M

Revenue: As of FY2025 Q2, the actual value is USD 651.6 M.

EPS: As of FY2025 Q2, the actual value is USD 11.67.

Net Sales: $262.8 million for Q2 2025, an increase of 4.9% compared to Q2 2024. On a currency neutral basis, sales increased 3.8%.
Cost of Goods Sold: $114.5 million for Q2 2025, compared to $105.9 million for Q2 2024.
Gross Margin: Decreased by approximately 1.3 percentage points compared to Q2 2024.
Segment Profit: $148.3 million for Q2 2025, compared to $144.6 million for Q2 2024.
Depreciation and Amortization: $17.8 million for Q2 2025, compared to $16.3 million for Q2 2024.

Net Sales: $388.8 million for Q2 2025, essentially flat compared to Q2 2024. On a currency neutral basis, sales decreased 0.7%.
Cost of Goods Sold: $191.8 million for Q2 2025, compared to $177.5 million for Q2 2024.
Gross Margin: Decreased by approximately 3.6 percentage points compared to Q2 2024.
Segment Profit: $197.0 million for Q2 2025, compared to $210.5 million for Q2 2024.
Depreciation and Amortization: $22.8 million for Q2 2025, compared to $20.1 million for Q2 2024.

Net Sales: $651.6 million for Q2 2025, an increase of 2.1% compared to Q2 2024. On a currency neutral basis, sales increased by approximately 1.0%.
Cost of Goods Sold: $306.3 million for Q2 2025, compared to $283.4 million for Q2 2024.
Gross Profit: $345.3 million for Q2 2025, compared to $355.1 million for Q2 2024.
Gross Margin: 53.0% for Q2 2025, compared to 55.6% for Q2 2024.
Selling, General and Administrative Expense: $207.7 million for Q2 2025, compared to $194.7 million for Q2 2024.
Research and Development Expense: $60.5 million for Q2 2025, compared to $58.9 million for Q2 2024.
Interest Expense: $12.6 million for Q2 2025, compared to $12.3 million for Q2 2024.
Foreign Currency Exchange (Gains) Losses, Net: $1.1 million loss for Q2 2025, compared to $1.7 million gain for Q2 2024.
Gains (Losses) from Change in Fair Market Value of Equity Securities and Loan Receivable: $334.4 million gain for Q2 2025, compared to $2.9 billion loss for Q2 2024.
Other Income, Net: $16.2 million for Q2 2025, compared to $18.2 million for Q2 2024.
Net Income (Loss): $317.8 million for Q2 2025, compared to - $2,165.5 million for Q2 2024.

Net Cash Provided by Operating Activities: $246.4 million for the six months ended June 30, 2025, compared to $167.4 million for the same period in 2024.
Net Cash Used in Investing Activities: $112.5 million for the six months ended June 30, 2025, compared to $74.0 million for the same period in 2024.
Net Cash Used in Financing Activities: $234.0 million for the six months ended June 30, 2025, compared to $96.6 million for the same period in 2024.

Core Business Focus: The company plans to continue focusing on the development and marketing of new products, particularly in the Life Science and Clinical Diagnostics segments. The strategic acquisition of Stilla Technologies is expected to strengthen the company’s offering in droplet digital PCR and facilitate entry into new molecular testing markets.
Non-Core Business: The company is monitoring global economic and geopolitical conditions, which remain uncertain and could impact future performance. The company is also addressing supply chain disruptions and inflationary pressures that have affected material costs and product pricing.